Skip to main content
Premium Trial:

Request an Annual Quote

Gene Editing Firm Editas Medicine Raises $43M in Series A Round

NEW YORK (GenomeWeb News) – Gene editing firm Editas Medicine today announced it has secured $43 million in Series A financing.

The financing was led by Flagship Ventures, Polaris Partners, and Third Rock Ventures. Partners Innovation Fund also participated.

Editas plans to use its genome editing technology to develop new therapeutics “that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.”

The company’s founders include Harvard professor George Church; MIT assistant professor Feng Zhang; University of California at Berkeley professor and Howard Hughes Medical Institute investigator Jennifer Doudna; Harvard associate professor Keith Joung; and Harvard professor and HHMI investigator David Liu.

Polaris Partners principal Kevin Bitterman is Editas’ interim president.

Filed under